References
- van Dorp E, Yassen A, Sarton E, et al. Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology. 2006;105(1):51–57.
- Darracq MA, Thornton SL. Respiratory depression following medications for opioid use disorder (MOUD)-approved buprenorphine product oral exposures; National Poison Database System 2003–2019. Clin Toxicol (Phila). 2020;7:1–10.
- Alhaddad H, Cisternino S, Declèves X, et al. Respiratory toxicity of buprenorphine results from the blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the blood-brain barrier in mice. Crit Care Med. 2012;40(12):3215–3223.
- Lam J, Baello S, Iqbal M, et al. The ontogeny of P-glycoprotein in the developing human blood-brain barrier: implication for opioid toxicity in neonates. Pediatr Res. 2015;78(4):417–421.
- Bauer M, Bamminger K, Pichler V, et al. Impaired clearance from the brain increases the brain exposure to metoclopramide in elderly subjects. Clin Pharm Ther. 2020. Online ahead of print. DOI:10.1002/cpt.2052